Hennion & Walsh Asset Management Inc. Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Hennion & Walsh Asset Management Inc. lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 31.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,286 shares of the biotechnology company’s stock after buying an additional 1,023 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in United Therapeutics were worth $1,536,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of UTHR. LSV Asset Management boosted its holdings in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after acquiring an additional 436,851 shares during the last quarter. Swedbank AB purchased a new position in United Therapeutics during the first quarter worth about $97,316,000. Nordea Investment Management AB grew its position in United Therapeutics by 677.6% in the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares in the last quarter. Canada Pension Plan Investment Board grew its position in United Therapeutics by 567.2% in the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares in the last quarter. Finally, Pacer Advisors Inc. increased its stake in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent analyst reports. Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. Oppenheimer raised their target price on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. UBS Group boosted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $361.33.

United Therapeutics Trading Down 0.4 %

Shares of UTHR stock opened at $348.65 on Friday. The stock has a market capitalization of $15.46 billion, a price-to-earnings ratio of 16.48, a PEG ratio of 1.35 and a beta of 0.57. The company’s fifty day simple moving average is $354.00 and its two-hundred day simple moving average is $312.79. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $377.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period last year, the company posted $5.24 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 24.72 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,812 shares of company stock valued at $35,251,926. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.